![Max Sakajja](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Max Sakajja
Corporate Officer/Principal bei
HANSA BIOPHARMA AB
Profil
Max Sakajja is currently VP & General Manager-Europe & International at Hansa Biopharma AB since 2025.
Former positions include Director-Mergers & Acquisitions at Swedish Orphan Biovitrum AB and Manager-Global Product & Service Development at Envirotainer AB. Education includes a graduate degree from the Royal Institute of Technology.
Aktive Positionen von Max Sakajja
| Unternehmen | Position | Beginn |
|---|---|---|
| HANSA BIOPHARMA AB | Corporate Officer/Principal | 01.01.2017 |
Ehemalige bekannte Positionen von Max Sakajja
| Unternehmen | Position | Ende |
|---|---|---|
Envirotainer AB
 Envirotainer AB Containers/PackagingProcess Industries Manufactures and sells temperature-controlled air cargo containers | Corporate Officer/Principal | - |
| SWEDISH ORPHAN BIOVITRUM AB | Corporate Officer/Principal | - |
Ausbildung von Max Sakajja
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
10
Beziehungen ersten Grades
4
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 4 |
|---|---|
Envirotainer AB
Envirotainer AB Containers/PackagingProcess Industries Manufactures and sells temperature-controlled air cargo containers | Process Industries |
Royal Institute of Technology
 Royal Institute of Technology Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Hansa Biopharma AB
 Hansa Biopharma AB Pharmaceuticals: MajorHealth Technology Develops therapies and medicines for the treatment of immunomodulatory | Health Technology |
Swedish Orphan Biovitrum AB
 Swedish Orphan Biovitrum AB Pharmaceuticals: MajorHealth Technology Manufactures and supplies pharmaceuticals and orphan drugs in the areas of hematology, immunology and specialty care | Health Technology |
